Diamantas’ FDA Tenure Could Stretch As Food, Supplement Decisions Loom

Brian Sylvester spoke with InsideHealthPolicy about the implications of Acting FDA Commissioner Kyle Diamantas potentially remaining in his role longer than expected while the search for a permanent FDA commissioner continues. Brian said the leadership change is unlikely to accelerate FDA’s food policy agenda because many priorities, including food chemical reassessments, GRAS reform, and dietary supplement oversight, were already underway before former Commissioner Marty Makary’s departure. He characterized the transition as a continuation rather than a major policy shift, noting that food and nutrition issues remain central to the administration’s “Make America Healthy Again” agenda. Brian explained, “My overall read is that, from my perspective on the food side, it continues to be business as usual.”

Read the full article.